Athanasios A. Panagiotopoulos

Dr. Athanasios A. Panagiotopoulos

orcid

Research Focus & Metrics

Academic Career Length

6Years (2021-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
24 June 2022 in Molecules
Verified
Journal Article
Open access
PDF file
SPStergios Pirintsos
Stergios Pirintsos
Athanasios A. PanagiotopoulosAthanasios A. Panagiotopoulos
Athanasios A. Panagiotopoulos
MBMichael Bariotakis
Michael Bariotakis
VDVangelis Daskalakis
Vangelis Daskalakis
Christos LionisChristos Lionis
Christos Lionis
ECElias Castanas
Elias Castanas
Ethnopharmacology, through the description of the beneficial effects of plants, has provided an early framework for the therapeutic use of natural compounds. Natural products, either in their native form or after crude extraction of their active ingredients, have long been used by different populations and explored as invaluable sources for drug design. The transition from traditional ethnopharmacology to drug discovery has followed a straightforward path, assisted by the evolution of isolation and characterization methods, the increase in computational power, and the development of specific chemoinformatic methods. The deriving extensive exploitation of the natural product chemical space has led to the discovery of novel compounds with pharmaceutical properties, although this was not followed by an analogous increase in novel drugs. In this work, we discuss the evolution of ideas and methods, from traditional ethnopharmacology to in silico drug discovery, applied to natural products. We point out that, in the past, the starting point was the plant itself, identified by sustained ethnopharmacological research, with the active compound deriving after extensive analysis and testing. In contrast, in recent years, the active substance has been pinpointed by computational methods (in silico docking and molecular dynamics, network pharmacology), followed by the identification of the plant(s) containing the active ingredient, identified by existing or putative ethnopharmacological information. We further stress the potential pitfalls of recent in silico methods and discuss the absolute need for in vitro and in vivo validation as an absolute requirement. Finally, we present our contribution to natural products’ drug discovery by discussing specific examples, applying the whole continuum of this rapidly evolving field. In detail, we report the isolation of novel antiviral compounds, based on natural products active against influenza and SARS-CoV-2 and novel substances active on a specific GPCR, OXER1.

Verified
Journal Article
Open access
PDF file
EKEvangelia Konstantinou
Evangelia Konstantinou
AGAristea Gioxari
Aristea Gioxari
MDMaria Dimitriou
Maria Dimitriou
GPGeorge I. Panoutsopoulos
George I. Panoutsopoulos
Athanasios A. PanagiotopoulosAthanasios A. Panagiotopoulos
Athanasios A. Panagiotopoulos
The most common malignancy in women is breast cancer. During the development of cancer, oncogenic transcription factors facilitate the overproduction of inflammatory cytokines and cell adhesion molecules. Antiapoptotic proteins are markedly upregulated in cancer cells, which promotes tumor development, metastasis, and cell survival. Promising findings have been found in studies on the cell cycle-mediated apoptosis pathway for medication development and treatment. Dietary phytoconstituents have been studied in great detail for their potential to prevent cancer by triggering the body’s defense mechanisms. The underlying mechanisms of action may be clarified by considering the role of polyphenols in important cancer signaling pathways. Phenolic acids, flavonoids, tannins, coumarins, lignans, lignins, naphthoquinones, anthraquinones, xanthones, and stilbenes are examples of natural chemicals that are being studied for potential anticancer drugs. These substances are also vital for signaling pathways. This review focuses on innovations in the study of polyphenol genistein’s effects on breast cancer cells and presents integrated chemical biology methods to harness mechanisms of action for important therapeutic advances.

19 December 2023 in Nutrients
Verified
Journal Article
Open access
PDF file
EKEvangelia Konstantinou
Evangelia Konstantinou
Athanasios A. PanagiotopoulosAthanasios A. Panagiotopoulos
Athanasios A. Panagiotopoulos
KAKonstantina Argyri
Konstantina Argyri
GPGeorgios Panoutsopoulos
Georgios Panoutsopoulos
MDMaria Dimitriou
Maria Dimitriou
AGAristea Gioxari
Aristea Gioxari
Breast cancer is the most frequent type of cancer in women. Oncogenic transcription factors promote the overproduction of cellular adhesion molecules and inflammatory cytokines during cancer development. Cancer cells exhibit significant upregulation of antiapoptotic proteins, resulting in increased cell survival, tumor growth, and metastasis. Research on the cell cycle-mediated apoptosis pathway for drug discovery and therapy has shown promising results. In fact, dietary phytoconstituents have been extensively researched for anticancer activity, providing indirect protection by activating endogenous defense systems. The role of polyphenols in key cancer signaling pathways could shed light on the underlying mechanisms of action. For instance, Rosmarinic Acid, a polyphenol constituent of many culinary herbs, has shown potent chemoprotective properties. In this review, we present recent progress in the investigation of natural products as potent anticancer agents, with a focus on the effect of Rosmarinic Acid on triple-negative BC cell lines resistant to hormone therapy. We highlight a variety of integrated chemical biology approaches aimed at utilizing relevant mechanisms of action that could lead to significant clinical advances in BC treatment.

Verified
Journal Article
Open access
PDF file
George NotasGeorge Notas
George Notas
Athanasios A. PanagiotopoulosAthanasios A. Panagiotopoulos
Athanasios A. Panagiotopoulos
RVRodanthi Vamvoukaki
Rodanthi Vamvoukaki
KKKONSTANTINA KALYVIANAKI
KONSTANTINA KALYVIANAKI
FKFoteini Kiagiadaki
Foteini Kiagiadaki
ECElias Castanas
Elias Castanas
Inflammation is important for the initiation and progression of breast cancer. We have previously reported that in monocytes, estrogen regulates TLR4/NFκB-mediated inflammation via the interaction of the Erα isoform ERα36 with GPER1. We therefore investigated whether a similar mechanism is present in breast cancer epithelial cells, and the effect of ERα36 expression on the classic 66 kD ERα isoform (ERα66) functions. We report that estrogen inhibits LPS-induced NFκB activity and the expression of downstream molecules TNFα and IL-6. In the absence of ERα66, ERα36 and GPER1 are both indispensable for this effect. In the presence of ERα66, ERα36 or GPER1 knock-down partially inhibits NFκB-mediated inflammation. In both cases, ERα36 overexpression enhances the inhibitory effect of estrogen on inflammation. We also verify that ERα36 and GPER1 physically interact, especially after LPS treatment, and that GPER1 interacts directly with NFκB. When both ERα66 and ERα36 are expressed, the latter acts as an inhibitor of ERα66 via its binding to estrogen response elements. We also report that the activation of ERα36 leads to the inhibition of breast cancer cell proliferation. Our data support that ERα36 is an inhibitory estrogen receptor that, in collaboration with GPER1, inhibits NFκB-mediated inflammation and ERα66 actions in breast cancer cells.

7 March 2025 in Clinics and Practice
Verified
Journal Article
Open access
PDF file
KLKonstantina Liva
Konstantina Liva
Athanasios A. PanagiotopoulosAthanasios A. Panagiotopoulos
Athanasios A. Panagiotopoulos
AFAlexandra Foscolou
Alexandra Foscolou
CHARALAMPIA AMERIKANOUCHARALAMPIA AMERIKANOU
CHARALAMPIA AMERIKANOU
AVAlkistis Vitali
Alkistis Vitali
AGAristea Gioxari
Aristea Gioxari
Background/Objectives: During the last decade, there has been an increased interest in phenolic compound-rich natural products as natural therapies for regulating the molecular pathways behind central obesity and associated metabolic disorders. The present scoping review presents the outcomes of clinical and preclinical studies examining the anti-obesity effects of high phenolic extra virgin olive oil (HP-EVOO) and its possible underlying molecular mechanisms. Methods: Studies published between 2014 and 2024 were searched via MEDLINE, Scopus, Cochrane, the Web of Science, Semantic Scholar, Google Scholar, Science.gov, and Clinicaltrials.gov databases. A combination of keywords and Boolean logic was used to search throughout the last decade in all databases, including “hyperglycemia” or “hypertension” or “metabolic syndrome” or “dyslipidemia” or “hyperlipidemia” or “hypoglycemia” or “obesity” or “macrovascular diabetic complications” or “microvascular diabetic complications” or “cardiovascular disease” or “overweight” or “insulin sensitivity” or “insulin resistance” and “extra virgin olive oil” or “high phenolic olive oil” and “human” or “animal model”. Results: The 10-year literature survey identified 21 studies in both animal models and humans, indicating that HP-EVOO improves inflammation, glycemic control, oxidative stress and endothelial function, potentially protecting against metabolic syndrome, hypertension and type 2 diabetes, even compared to EVOO. Moreover, HP-EVOO’s antiplatelet effect and improvement in HDL functionality reduce cardiovascular risk. Conclusions: The evidence presented in this study demonstrates that HP-EVOO represents an effective preventive and therapeutic dietary approach to cardiometabolic diseases.

7 October 2021 in Molecules
Verified
Journal Article
Open access
PDF file
Athanasios A. PanagiotopoulosAthanasios A. Panagiotopoulos
Athanasios A. Panagiotopoulos
IKIoannis Karakasiliotis
Ioannis Karakasiliotis
DKDanai-Maria Kotzampasi
Danai-Maria Kotzampasi
MDMarios Dimitriou
Marios Dimitriou
GSGeorge Sourvinos
George Sourvinos
VDVangelis Daskalakis
Vangelis Daskalakis
3CL-Pro is the SARS-CoV-2 main protease (MPro). It acts as a homodimer to cleave the large polyprotein 1ab transcript into proteins that are necessary for viral growth and replication. 3CL-Pro has been one of the most studied SARS-CoV-2 proteins and a main target of therapeutics. A number of drug candidates have been reported, including natural products. Here, we employ elaborate computational methods to explore the dimerization of the 3CL-Pro protein, and we formulate a computational context to identify potential inhibitors of this process. We report that fortunellin (acacetin 7-O-neohesperidoside), a natural flavonoid O-glycoside, and its structural analogs are potent inhibitors of 3CL-Pro dimerization, inhibiting viral plaque formation in vitro. We thus propose a novel basis for the search of pharmaceuticals as well as dietary supplements in the fight against SARS-CoV-2 and COVID-19.